About Us

doctor with patient

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders.

Migraine Attack

  • May start with a warning phase involving tiredness and abnormal sensitivity to noise, lights or smells
  • May be preceded by “Aura” - flashing lights, small areas of temporary visual loss and tingling or numbness on one side of the face Headache usually one-sided, throbbing, and moderate or severe in intensity, worsening by movement
  • Accompanied by nausea and vomiting and light and sound sensitivity
  • Lasts from 4 to 72 hours and be followed by tiredness, mood changes and difficulty concentrating
  • Migraineurs suffer on average three migraines per month

Media Coverage

Press Releases